Y-mAbs Announces Publication of Preclinical GD2-SADA Data at 2024 ASCO Annual Meeting
NEW YORK, June 01, 2024 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical […]
Y-mAbs Announces New Interim Analysis of Phase 2 Data for Naxitamab at 2024 ASCO Annual Meeting
NEW YORK, June 01, 2024 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical […]
Kymera Therapeutics Presents New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting
KT-253 demonstrates initial clinical proof of concept in patients with tumor types shown to be sensitive in preclinical models, including […]
Purple Biotech Announces Positive Late-Breaking Interim Randomized Phase 2 Data at ASCO 2024 Demonstrating CM24 Improved Overall Survival and other Efficacy Endpoints in Pancreatic Cancer
26% reduction in risk of death (HR=0.74) and 28% risk reduction in progression or death (HR=0.72) in previously-treated patients administered […]
Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response
Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to […]
Cullinan Therapeutics Announces Positive Initial Data from Pivotal Phase 2b REZILIENT1 Study of Zipalertinib
CAMBRIDGE, Mass., June 01, 2024 (GLOBE NEWSWIRE) — Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on developing modality-agnostic […]
Aduro Clean Technologies kündigt Privatplatzierung von bis zu 2,5 Mio. USD an
NICHT ZUR VERTEILUNG AN NACHRICHTENAGENTUREN DER VEREINIGTEN STAATEN ODER ZUR VERBREITUNG IN DEN VEREINIGTEN STAATEN LONDON, Ontario, June 01, 2024 […]
Aduro Clean Technologies annonce un placement privé d’un montant maximal de 2,5 millions de dollars
NE PAS DISTRIBUER AUX AGENCES DE PRESSE DES ÉTATS-UNIS ET NE PAS DIFFUSER AUX ÉTATS-UNIS LONDON, Province de l’Ontario, 01 […]
